belvarafenib   Click here for help

GtoPdb Ligand ID: 11544

Synonyms: Example 116 [WO2013100632A1] | GDC-5573 | HM95573 | RG6185
PDB Ligand
Compound class: Synthetic organic
Comment: Belvarafenib is a clinical stage, oral RAF kinase inhibitor that is being developed in a collaboration between Genentech and Hanmi Pharmaceuticals. The chemical structure is one of those claimed in Hanmi patent WO2013100632A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 134.06
Molecular weight 478.08
XLogP 4.36
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1ccc2c(c1NC(=O)c1csc3c1ncnc3N)ccnc2Nc1cccc(c1F)Cl
Isomeric SMILES Cc1ccc2c(c1NC(=O)c1csc3c1ncnc3N)ccnc2Nc1cccc(c1F)Cl
InChI InChI=1S/C23H16ClFN6OS/c1-11-5-6-13-12(7-8-27-22(13)30-16-4-2-3-15(24)17(16)25)18(11)31-23(32)14-9-33-20-19(14)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)
InChI Key KVCQTKNUUQOELD-UHFFFAOYSA-N
References
1. Bae IH, Son JB, Han SM, Kwak EJ, Kim HS, Song JY, Byun EY, Jun SA, Ahn YG, Suh KH. (2013)
THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES.
Patent number: WO2013100632A1. Assignee: Hanmi Pharm Co. Priority date: 30/12/2011. Publication date: 04/07/2013.